Citadel Advisors’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.89M | Sell |
17,600
-18,100
| -51% | -$11.6M | ﹤0.01% | 3273 |
|
|
2025
Q4 | $24.2M | Buy |
35,700
+17,200
| +93% | +$11.7M | ﹤0.01% | 2149 |
|
|
2025
Q3 | $11.8M | Buy |
18,500
+200
| +1% | +$121K | ﹤0.01% | 3016 |
|
|
2025
Q2 | $9.82M | Sell |
18,300
-17,300
| -49% | -$8.27M | ﹤0.01% | 3047 |
|
|
2025
Q1 | $15M | Sell |
35,600
-4,100
| -10% | -$1.78M | ﹤0.01% | 2362 |
|
|
2024
Q4 | $16.4M | Buy |
39,700
+3,100
| +8% | +$1.36M | ﹤0.01% | 2388 |
|
|
2024
Q3 | $18.5M | Buy |
36,600
+4,600
| +14% | +$2.23M | ﹤0.01% | 2129 |
|
|
2024
Q2 | $15.6M | Sell |
32,000
-6,300
| -16% | -$3.16M | ﹤0.01% | 2265 |
|
|
2024
Q1 | $20.7M | Buy |
38,300
+5,200
| +16% | +$2.84M | ﹤0.01% | 2027 |
|
|
2023
Q4 | $18.4M | Buy |
33,100
+5,300
| +19% | +$2.49M | ﹤0.01% | 2105 |
|
|
2023
Q3 | $12.2M | Buy |
27,800
+1,500
| +6% | +$748K | ﹤0.01% | 2444 |
|
|
2023
Q2 | $13.2M | Sell |
26,300
-92,600
| -78% | -$44.4M | ﹤0.01% | 2335 |
|
|
2023
Q1 | $59.5M | Sell |
118,900
-16,400
| -12% | -$7.85M | 0.01% | 941 |
|
|
2022
Q4 | $55.2M | Buy |
135,300
+22,400
| +20% | +$8.7M | 0.01% | 1047 |
|
|
2022
Q3 | $36.8M | Buy |
112,900
+51,100
| +83% | +$18.8M | 0.01% | 1306 |
|
|
2022
Q2 | $21.7M | Sell |
61,800
-4,700
| -7% | -$1.92M | 0.01% | 1765 |
|
|
2022
Q1 | $36.4M | Sell |
66,500
-7,900
| -11% | -$4.16M | 0.01% | 1370 |
|
|
2021
Q4 | $49M | Sell |
74,400
-18,600
| -20% | -$11.7M | 0.01% | 1186 |
|
|
2021
Q3 | $57.8M | Sell |
93,000
-3,400
| -4% | -$2.28M | 0.01% | 1016 |
|
|
2021
Q2 | $60.9M | Sell |
96,400
-21,700
| -18% | -$12M | 0.01% | 974 |
|
|
2021
Q1 | $57.8M | Buy |
118,100
+67,000
| +131% | +$33.6M | 0.01% | 938 |
|
|
2020
Q4 | $25.5M | Buy |
51,100
+22,200
| +77% | +$9.93M | 0.01% | 1558 |
|
|
2020
Q3 | $11.4M | Buy |
28,900
+11,500
| +66% | +$4.25M | ﹤0.01% | 2147 |
|
|
2020
Q2 | $5.75M | Sell |
17,400
-1,900
| -10% | -$550K | ﹤0.01% | 2897 |
|
|
2020
Q1 | $4.67M | Sell |
19,300
-25,200
| -57% | -$6.58M | ﹤0.01% | 2805 |
|
|
2019
Q4 | $11.6M | Sell |
44,500
-11,600
| -21% | -$3.06M | 0.01% | 2047 |
|
|
2019
Q3 | $15.3M | Buy |
56,100
+29,900
| +114% | +$8.32M | 0.01% | 1734 |
|
|
2019
Q2 | $7.21M | Sell |
26,200
-14,200
| -35% | -$3.5M | ﹤0.01% | 2585 |
|
|
2019
Q1 | $9.03M | Buy |
40,400
+5,000
| +14% | +$1.03M | ﹤0.01% | 2206 |
|
|
2018
Q4 | $6.58M | Buy |
35,400
+1,000
| +3% | +$205K | ﹤0.01% | 2419 |
|
|
2018
Q3 | $8.59M | Buy |
34,400
+1,600
| +5% | +$388K | ﹤0.01% | 2305 |
|
|
2018
Q2 | $7.15M | Buy |
32,800
+12,200
| +59% | +$2.51M | ﹤0.01% | 2310 |
|
|
2018
Q1 | $3.94M | Sell |
20,600
-6,300
| -23% | -$1.16M | ﹤0.01% | 2748 |
|
|
2017
Q4 | $4.21M | Buy |
26,900
+15,300
| +132% | +$2.41M | ﹤0.01% | 2688 |
|
|
2017
Q3 | $1.8M | Sell |
11,600
-2,900
| -20% | -$458K | ﹤0.01% | 3520 |
|
|
2017
Q2 | $2.34M | Buy |
14,500
+6,400
| +79% | +$1.04M | ﹤0.01% | 2965 |
|
|
2017
Q1 | $1.25M | Buy |
8,100
+1,800
| +29% | +$248K | ﹤0.01% | 3676 |
|
|
2016
Q4 | $739K | Buy |
+6,300
| New | +$719K | ﹤0.01% | 4296 |
|
Other funds holding IDXX
VCM
VPM
Citadel Advisors's IDXX Position: Q1 2026 in Review
Citadel Advisors increased its Idexx Laboratories (IDXX) stake by 391% in Q1 2026, buying an estimated $44.7M and bringing the position to 87,566 shares worth $49.2M. The position accounts for 0.01% of the portfolio, ranked #1381.
Citadel Advisors first reported a position in IDXX in Q2 2013 and has held it in 47 quarters since. The position peaked at $356M in Q1 2023. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Citadel Advisors held 87,566 shares of Idexx Laboratories worth $49.2M as of Q1 2026.
- Citadel Advisors bought 69,723 Idexx Laboratories shares in Q1 2026, an estimated $44.7M.
- Idexx Laboratories made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1381 holding.
- Citadel Advisors first reported a position in Idexx Laboratories in Q2 2013 and has held it in 47 quarters since.
- Citadel Advisors's Idexx Laboratories position peaked at $356M in Q1 2023.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.